

Short CV



1. **Name of the Employee:** Subhash Chand
2. **Email id:** schand@nib.gov.in
3. **Designation:** Scientist Grade III
4. **Division/LAB:** Therapeutic Antibody Laboratory
5. **Educational Qualification:**

Degree / Diploma	University/Institute	Year
M.Sc. (Microbiology)	Himachal Pradesh University, Shimla, India	2008
Postgraduate Diploma in Business Administration (PGDBA)	Symbiosis, Pune, India	2011
Ph.D. (Biotechnology)	Amity University, NOIDA, India	Pursuing

6. **Year of Joining:** 2010

7. **Professional Experience:**

Over 13 years of research experience in Quality Control & Regulations of Biopharmaceutical (Viral Vaccines & Therapeutic Monoclonal Antibodies) and Pharmaceutical products. Worked previously in Torrent Pharmaceuticals Ltd. (Baddi, H.P., India) from 2008 to 2010 and thereafter joined National Institute of Biologicals (NIB) in March, 2010.

Notified by Ministry of Health & Family Welfare, Govt. of India as 'Govt. Analyst' for Therapeutic Monoclonal antibodies (Rituximab, Trastuzumab, Bevacizumab, Adalimumab) vide Gazette notification no. 4271(E) dt. 26.11.2019. Inspected many Biopharmaceutical companies as 'Subject Expert' in various Regulatory Inspections with Central Drugs Standards and Control Organization (CDSCO) including inspections for Good Manufacturing Practices (GMPs), Chemistry Manufacturing and Control (CMC), Adverse Drug Reaction (ADR).

Expert Member in various Committees of National Institutions like ISO REMCO National Mirror Committee-Bureau of Indian Standards (BIS), Bioassay Laboratory of Translational Health Science and Technology Institute (THSTI)-Faridabad, Indian Pharmacopoeia Commission- Ghaziabad, CSIR IMTECH-Chandigarh.

Published more than 15 research papers in International journals. Guided more than 50 B.Sc. / M.Sc. / B. Tech (Biotech) / M. Tech (Biotech) students in dissertation work.

8. Major Publications:

- I. Anu Prakash, Nripendra N. Mishra, Utpreksha Vaish, Sonia Sharma, Apoorva Anand, Richi V. Mahajan, J. P. Prasad, **Subhash Chand***. Comparative analytical profiling of Bevacizumab biosimilars marketed in India: a national control laboratory study. *3Biotech*. 2020;10:516. doi: 10.1007/s13205-020-02506-9. (*Corresponding Author).
- II. **Subhash Chand**, Utpreksha Vaish, Anu Sharma, Nripendra Nath Mishra, J.P. Prasad, Richi V. Mahajan. A reliable assay for ensuring the biological activity of anti T lymphocyte immunoglobulin as an alternate to compendial flow cytometry method. *Biologicals*. 2020; 65:33-38.doi: 10.1016/j.biologicals.2020.01.002
- III. **Subhash Chand**, R. V. Mahajan, J.P. Prasad, D. K. Sahoo, K.N. Mihooliya, M.S. Dhar, G. Sharma. A comprehensive review on microbial L-asparaginase: Bioprocessing, characterization, and industrial applications. *Biotechnol Appl Biochem*. 2020. DOI: 10.1002/bab.1888.
- IV. Jaipal Meena, Shivani Sood, Neha Rani, Roshita Bisht, Manjula Kiran, Reba Chhabra, Surinder Singh, **Subhash Chand***. Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory. *Biologicals*. 2019; 59:72-73. DOI: 10.1016/j.biologicals.2019.03.005. (*Corresponding Author).
- V. **Subhash Chand**, Birendra Kumar, Vivek Morris Prathap, Surinder Singh, Richi V. Mahajan. Quality assurance of Rituximab (anti-CD 20) antibodies by potency testing: Determining the System Suitability Criteria and Sample Acceptance Criteria. *Current Science*. 2018; 114(12). DOI: 10.18520/cs/v114/i12/2513-2518.
- VI. Sandra Prior *et al.* and Participant of the Study – **Subhash Chand***. International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. *mAbs*. 2017. DOI: 10.1080/19420862.2017.1386824. (*WHO-NIBSC International collaborative study Participant).
- VII. Kabita Chatterjee, Shamsuz Zaman, Rahul Chaurasia, Surinder Singh, Shawn Keil, Shalini Tiwari, Akanksha Bisht, Nitin Aggarwal, Diptirajan raut, **Subhash Chand**, Kallol Saha. Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with *Staphylococcus epidermidis*. *Asian J Transfus Sci*. 2016;10(2): 127–131.